| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Through the immunohistochemical analysis, we have reported over expression of FOXA1 cause short time before acquire castration resistance. We have identified overexpression of aminoacid transporter; LAT1 in castration resistant prostate cancer and reporterd anti-androgen therapy incraese LAT1 expression, thus reported singificance of LAT1 in novel castration resistant mechanism(J Urol 2016). Through the analyisis of prostate cancer patients received hormonal therapy, we have identified testosterone 20ng/dL was the significant prognostic factor. Thus proposed testosterone 20ng/dL should be the ideal castration level in prostate cancer patients during hormonal therapy(J Urol 2015).
|
